Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Prellis Biologics
StartUPDATES: New developments from healthcare startups
Advancing its core technology offering, Equiva announced a major upgrade to its health relationship management (HRM) platform, an omnichannel SaaS offering that helps healthcare organizations develop and retain long-term customer relationships. The enhancements improve user experience, data collection, reporting, device tracking and extensibility. “Moving to a more customer-centric model is imperative for healthcare providers,” said Equiva CEO Nir Altman.
Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS™) based on human lymph node organoids (LNO™). The collaboration leverages Prellis’ EXIS platform that can break tolerance mechanisms in vitro to create high affinity human antibodies targeting human proteins.
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
SAN FRANCISCO, Dec. 15, 2021 /PRNewswire-PRWeb/ -- Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. "The EXIS platform offers unprecedented in vitro access to a functional human immune system.
SOSV Announces Launch of IndieBio New York
The SOSV IndieBio San Francisco team World’s leading life sciences accelerator expands to New York City beginning April 2020 — Call for applications open now (NEW YORK, January 7th, 10:30am EST) — SOSV, the world’s most active investor in both life sciences and hardware, announced that the inaugural cohort of IndieBio New York will start in Manhattan in April 2020, with applications being accepted beginning today.
Prellis Biologics Raises $8.7 Million, Reports Progress in 3D Holographic Tissue Printing
Khosla Ventures leads Series A investment in human tissue engineering company Prellis, backing Prellis' mission to create viable human tissue and organs for research and transplant. San Francisco, CA---Prellis Biologicstoday announced that Khosla Ventures has led an $8.7 million Series A investment in the company.
Human Tissue Engineering Company Prellis Biologics Raises $8.7 Million Series A Round; Announces First Animal Transplant of Its 3D-Printed Tissue
Prellis Biologics today announced that Khosla Ventures has led an $8.7 Series A investment in the company. The announcement comes as Prellis has reached major tissue engineering milestones in its mission to use 3D holographic printing to create 3D tissue and organs for research and transplantation. This press release features multimedia.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Prellis
Contact Prellis, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack